Teva Pharmaceutical Industries, the world's largest generic drugmaker, met forecasts with a 14% rise in quarterly earnings on strong sales growth in Europe following last year's Ratiopharm acquisition.
Israel-based Teva, which last week announced a deal to acquire U.S. specialty drugmaker Cephalon for $6.8 billion, posted first-quarter earnings before certain items of $1.04 per share. Sales rose 12.1% to $4.1 billion.
Teva was expected to earn $1.04 on revenue of $4.27 billion, according to a Thomson Reuters I/B/E/S poll.
Sales of Copaxone, the leading multiple sclerosis treatment with a global market share of 31%, increased 14% to $907 million.
Teva reiterated its outlook, excluding anticipated acquisitions, for 2011 revenue of $18.5-$19 billion and earnings per share excluding items of $4.90-$5.20. Teva declared a dividend of 0.80 shekel.
Related Articles :
Keywords : acquisitions Cephalon Copaxone generic drugs generics multiple sclerosis Pharmaceuticals Q1 2011 Ratiopharm sales and profits Teva Teva buys Cephalon Teva buys Ratiopharm Teva Pharmaceutical Industries
Email requestCompany HomepageTEVA Pharmaceutical Ind.Ltd
Basel Str. 5
49131 Petach Tikva
Israel
Tel: +972 9267267
Fax: +972 9267423
Web: www.tevapharm.com
Reader comments (0)